T cell transduction to produce homogeneous immune cells for clinical research purposes
CompanyMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
The company Miltenyi Biotec has developed the fully automated CliniMACS Prodigy platform for an easily reproducible and standardized production process of genetically modified T cells to research their diagnostic and therapeutic potential against blood cancer. The platform includes two applications. CliniMACS Prodigy TCT (T cell transduction process) enables the production of chimeric antigen receptor T cells (CAR-T cells) from whole blood, peripheral blood mononuclear cells (PBMCs) or fresh leukapheresis. CliniMACS Prodigy TCT-LS (T cell transduction process- large scale) offers the user greater cell culture capacity and was developed for the production of T cell receptor cells (TCR T cells). After loading the system with the patient's blood samples, the CliniMACS Prodigy takes over all critical work steps. Magnetic beads integrated into the platform enable efficient isolation of CD4 and CD8 cells without activating them. At the same time, contaminated immune cells are safely removed from the system. To support the subsequent work steps (T cell activation, genetic modification of the isolated cells through viral transduction and their proliferation in culture), Milentyi offers specially developed reagents, media and additional components that promote transduction. By integrating sampling bags into the tubing system, researchers can also monitor and analytically evaluate the process progress and the quality of the cells throughout the entire manufacturing process using clinical flow cytometry. Overall, the method proves to be a comprehensive approach to the standardized development of clinically relevant immune cells that are needed to advance research into personalized T cell therapies against blood cancers (such as leukaemias or lymphomas).
Clinical-grade TCR engineered T cell and CAR T cell manufacturing via viral transduction
macs@miltenyibiotec.de
Added on: 02-15-2024
[1] https://www.miltenyibiotec.com/DE-en/applications/by-cell-type/t-cells/CAR-T-cell-manufacturing.html
